Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carcinoid tumour.

M K G McStay1, M E Caplin

  • 1Department of Gastroenterology, Royal Free Hospital, London, UK.

Minerva Medica
|November 1, 2002
PubMed
Summary
This summary is machine-generated.

Carcinoid tumours are rare and challenging neoplasms. Advances in diagnosis, like plasma chromogranin A, and diverse treatments, including somatostatin analogues and interventional therapies for liver metastases, improve management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

Endocrine-related cancer·2024
Same author

Pollution and respiratory disease: can diet or supplements help? A review.

Respiratory research·2018
Same author

A comparison of CellCollector with CellSearch in patients with neuroendocrine tumours.

Endocrine-related cancer·2016
Same author

Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.

The Journal of clinical endocrinology and metabolism·2015
Same author

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms.

British journal of cancer·2013

Area of Science:

  • Oncology
  • Endocrinology
  • Diagnostic Imaging

Background:

  • Carcinoid tumours are rare neoplasms often presenting with vague symptoms, posing diagnostic challenges.
  • The carcinoid syndrome, caused by hormone secretion, is a recognized clinical manifestation.
  • These tumours can exhibit aggressive growth and are associated with multiple endocrine neoplasia type 1 and other cancers.

Purpose of the Study:

  • To review recent advancements in the diagnosis and management of carcinoid tumours.
  • To provide an overview of current and emerging therapeutic strategies.
  • To highlight the need for a multidisciplinary approach and further research.

Main Methods:

  • Review of biochemical diagnostic improvements, including plasma chromogranin A.

Related Experiment Videos

  • Evaluation of imaging modalities such as Indium-111 Octreotide scintigraphy and positron emission tomography.
  • Discussion of therapeutic options, encompassing somatostatin analogues, surgery, chemotherapy, biotherapy, and receptor-targeted therapy.

    • Main Results:

    • Plasma chromogranin A offers improved biochemical diagnosis.
    • Various imaging techniques aid in tumour localization and characterization.
    • A spectrum of therapeutic options exists, including medical, surgical, and interventional approaches for liver metastases.

    Conclusions:

    • A multidisciplinary approach is essential for optimal diagnosis and treatment of carcinoid tumours.
    • Further research and controlled clinical trials are necessary to establish the efficacy of various treatment options.
    • Collaboration is crucial for advancing the understanding and management of these rare neoplasms.